Foreign vaccine firm faces administrative disposition for false advertisements

Amid growing controversy over the efficacy of imported influenza vaccine, the Korea Food and Drug Administration said on October 27 that it is considering taking administrative measures to GlaxoSmithKline (GSK) for falsely advertising its influenza vaccine, Fluarix, as more effective than others without reliable evidences.

According to the KFDA, GSK distributed leaflets to hospitals, claimin...